Home
    Abstracts
    Registration
    Accommodation
    Contact
Home
Welcome Note
Congress Chairpersons
Section Heads
International Board
List of Main Topics
List of Faculty
Speaker Guidelines
Timetable
Scientific Program
Meet the Experts Breakfast Session
Poster Presentations
E-Poster schedule
Best Poster Awards
Poster Presentation Guidelines
Registration
General Information
Italian Agent
Before you travel...
Accommodation
Swissôtel The Bosphorus
CME
Invitation Letter
Sponsorship & Exhibition
Sponsors
Exhibitors
Educational Tour
Endorsements
Partners & Links
About Istanbul
Previous CONy Congresses
Webcasting
CONy 2013 Webcasting - Selected
CONy 2012 Webcasting
CONy 2011 Webcasting
CONy 2010 Webcasting
  

 
  CONy 2013 Webcasting - Selected Print
Click here for Hall A - STROKE
Click here for Hall A - MULTIPLE SCLEROSIS
Click here for Hall C - PARKINSON'S DISEASE
Click here for Hall C - EPILEPSY

Hall A - PLENARY LECTURES
Thursday, April 11, 2013
 
On Sextus Empiricus and medical skepticism
S. Baloyannis, Greece
Is neurorecovery a valid concept?
D. Muresanu, Romania
Hall A - STROKE
Friday, April 12, 2013
Is AIS evaluation-multimodal CT superior to MRI?
Yes: K. Butcher, Canada
Is AIS evaluation
multimodal CT
superior to MRI?
No: L. Ranganathan,
India
Is AIS evaluation
multimodal CT
superior to MRI?
Commentator:
D. Heiss, Germany
AF-related stroke should be treated only with new anticoagulants
Yes: A. Shuaib, Canada
AF-related stroke should be treated only with new anticoagulants
No: K. Kutluk, Turkey
AF-related stroke should be treated only with new anticoagulants
Commentator:
M. Brainin, Austria
PFO - to close
or not to close?
To close:
N. Uzuner, Turkey
PFO - to close
or not to close?
Not to close:
L. Csiba, Hungary
PFO - to close
or not to close?
Commentator:
N. Bornstein, Israel
Expensive mistakes in stroke thrombolysis
J. Norris, UK
Expensive mistakes in stroke thrombolysis
Commentator:
D. Spence, Canada
 
Hall A - MULTIPLE SCLEROSIS
Saturday, April 13, 2013
Are the present outcome measures for assessing efficacy of disease modifying therapies in MS clinically relevant?
Debate host:
C. Hawkes, UK
Are the present outcome measures for assessing efficacy of disease modifying therapies in MS clinically relevant?
Yes: O. Aktas, Germany
Will environmental and behavioral changes alter susceptibility or
the course of MS?
G. Ebers, UK
Is disability progression in MS due to an inflammatory or neurodegenerative process?
A. Bar-Or, Canada
Is disability progression in MS due to an inflammatory or neurodegenerative process?
An inflammatory disease: W. Brück, Germany
Is disability progression in MS due to an inflammatory or neurodegenerative process?
A neurodegenerative disease:
A. Chaudhuri, UK
MS - Environmental or genetic?
MS is primarily a genetic process: G. Ebers, UK
MS - Environmental or genetic?
MS is primarily an environmental process:
C. Hawkes, UK
Primary progressive MS and secondary progressive MS are different manifestations of a single disease
Debate host:
R. Milo, Israel
Primary progressive MS and secondary progressive MS are different manifestations of a single disease
Yes: O. Kantarci, USA
Primary progressive MS and secondary progressive MS are different manifestations of a single disease
No: A. Chaudhuri, UK
Are MS and NMO two polarized diseases? Does this have treatment implications?
Debate host:
M. Keegan, USA
Are MS and NMO two polarized diseases? Does this have treatment implications?
Yes: B. Weinshenker, USA
Are MS and NMO two polarized diseases? Does this have treatment implications?
No: W. Brück, Germany
Changing perspectives in MS: Pursuing efficacy; managing risk
P. Vermersch, France
Targeted therapy in MS: Should we aim at B or T lymphocytes?
Therapy should be targeted against B cells:
A. Bar-Or, Canada
Radiologically isolated syndrome (RIS) patients are at high risk of developing MS and warrant treatment
with disease
modifying drugs (DMD)
Debate host:
P. Vermersch, France
Radiologically isolated syndrome (RIS) patients are at high risk of developing MS and warrant treatment with disease modifying
drugs (DMD)
No: A. Siva, Turkey
New Players in MS
Gilenya:
G. Akman Demir
,
Turkey
New C
New Players in MS
Teriflunomide:
M. Freedman, Canada
New Players in MS
BG12:
O. Bajenaru
, Romania
New Players in MS
Alemtuzumab:
E. Havrdova
,
Czech Republic
New Players in MS
Laquinimod:
H.-P. Hartung
, Germany

New Players in MS
Ocrelizumab:
D. Leppert
, Switzerland

New Players in MS
Daclizumab: R. Milo, Israel

Hall C - PARKINSON'S DISEASE
Friday, April 12, 2013
Is MCI-PD a useful diagnosis?
Yes: M. Emre, Turkey
Is MCI-PD a useful diagnosis?
No: A.D. Korczyn, Israel
Are the current outcome parameters in PD clinical trials clinically relevant?
Commentator;
M. Emre, Turkey
Is molecular imaging really helpful in diagnosing PD?
Yes: A. Antonini, Italy

 
Is molecular imaging really helpful in diagnosing PD?
No: V. Srinivasan, India
Is molecular imaging really helpful in diagnosing PD?
Commentator:
L. Battistin, Italy
Which is the better dopaminomimetic therapy in PD?
Oral TBN:
L. Vecsei, Hungary
Which is the better dopaminomimetic therapy in PD?
Transdermal:
A. Antonini, Italy
Which is the better dopaminomimetic therapy in PD?
Commentator:
M. Onofrj, Italy
All PD patients should start treatment with levodopa and go slow
No: C. Akbostanci, Turkey
All PD patients should start treatment with levodopa and go slow
Commentator:
M. Emre, Turkey
Do vascular factors influence the
course of PD?
Yes: I. Rektor, Czech Republic
Do vascular factors influence the
course of PD?
Commentator:
K. Jellinger, Austria
How large is the advanced space of PD, when does it really start in PD?
View 2: T. van Laar, The Netherlands
How large is the advanced space of PD, when does it really start in PD?
Commentator:
M. Emre, Turkey
When should DBS for PD be initiated?
D. Binder, USA

When should DBS for PD be initiated?
B. Elibol, Turkey

When should DBS for PD be initiated
Commentator: V.Srinivasan, India
Adjunctive therapy should be initiated as soon as wearing-off is detected
No: B. Elibol, Turkey
Adjunctive therapy should be initiated as soon as wearing-off is detected
R. Inzelberg, Israel
 
Debate: NMDA antagonists are useful in PD
Yes: L. Vecsei, Hungary
Debate: NMDA antagonists are useful in PD
No: M. Onofrj, Italy
Debate: NMDA antagonists are useful in PD
Commentator:
R. Inzelberg, Israel
Hall C - EPILEPSY
Saturday, April 13, 2013
Does genetic testing have a role in epilepsy management?
Yes: P. Striano, Italy
Does genetic testing have a role in epilepsy management?
Commentator:
I. Blatt, Israel
Should patients with cortical strokes be treated prophylactically against seizures?
Yes: N. Dericioglu, Turkey
Should patients with cortical strokes be treated prophylactically against seizures?
No: W. Theodore, USA
Should patients with cortical strokes be treated prophylactically against seizures?
Commentator:
K. Agan, Turkey

EEG is usually necessary when diagnosing epilepsy
No: M. Holtkamp, Germany

EEG is usually necessary when diagnosing epilepsy
Commentator:
V. Kimiskidis, Greece
Who should have drugs stopped and who should be continued?
Speaker:
C. Ozkara, Turkey
Who should have drugs stopped and who should be continued?
Commentator:
E. Ben-Menachem, Sweden

Proposition: DBS should only be used after VNS has failed
Yes: M. Sperling, USA

Proposition: DBS should only be used after VNS has failed
No: P. Boon, Belgium

Proposition: DBS should only be used after VNS has failed
Commentator:
M. Holtkamp, Germany
Are some antiepileptic drugs preferred during pregnancy?
Yes: V. Kimiskidis, Greece

Are some antiepileptic drugs preferred during pregnancy?
No: E. Beghi, Italy

Are some antiepileptic drugs preferred during pregnancy?
Commentator:
E. Ben-Menachem, Sweden
Should enzyme-inducing antiepileptic drugs be avoided?
Yes: M. Sperling, USA

Should enzyme-inducing antiepileptic drugs be avoided?
No: W. Theodore, USA

Should enzyme-inducing antiepileptic drugs be avoided?
Commentator:
E. Beghi, Italy
Is aggressive therapy justified for all types of status epilepticus?
Yes: K. Agan, Turkey
 
Is aggressive therapy justified for all types of status epilepticus?
No: P. Boon, Belgium


Home   
Copyright © 2007 comtecmed.com. All rights reserved.   The website was last updated on 05/20/2013